KR102616249B1 - 신경영양성 인자인 티로신 키나제 수용체 억제제로서 사용되는 아미노 피라졸로피리미딘 화합물 - Google Patents

신경영양성 인자인 티로신 키나제 수용체 억제제로서 사용되는 아미노 피라졸로피리미딘 화합물 Download PDF

Info

Publication number
KR102616249B1
KR102616249B1 KR1020197015241A KR20197015241A KR102616249B1 KR 102616249 B1 KR102616249 B1 KR 102616249B1 KR 1020197015241 A KR1020197015241 A KR 1020197015241A KR 20197015241 A KR20197015241 A KR 20197015241A KR 102616249 B1 KR102616249 B1 KR 102616249B1
Authority
KR
South Korea
Prior art keywords
group
optionally substituted
phenyl
hydroxy
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197015241A
Other languages
English (en)
Korean (ko)
Other versions
KR20190067913A (ko
Inventor
리 주
위엔동 후
웨이 우
리구앙 다이
시아오웨이 두안
얀칭 양
잉회이 순
용신 한
용 펑
판셩 콩
홍 루오
링 양
홍지앙 수
멍 구오
자오바이 종
샨춘 왕
Original Assignee
치아타이 티안큉 파마수티컬 그룹 주식회사
켄타우루스 바이오파마 컴퍼니 리미티드
롄윈강 룬종 파마슈티컬 컴퍼니, 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 치아타이 티안큉 파마수티컬 그룹 주식회사, 켄타우루스 바이오파마 컴퍼니 리미티드, 롄윈강 룬종 파마슈티컬 컴퍼니, 리미티드 filed Critical 치아타이 티안큉 파마수티컬 그룹 주식회사
Publication of KR20190067913A publication Critical patent/KR20190067913A/ko
Application granted granted Critical
Publication of KR102616249B1 publication Critical patent/KR102616249B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020197015241A 2016-10-28 2017-10-27 신경영양성 인자인 티로신 키나제 수용체 억제제로서 사용되는 아미노 피라졸로피리미딘 화합물 Active KR102616249B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201610970314 2016-10-28
CN201610970314.3 2016-10-28
CN201710044000 2017-01-21
CN201710044000.5 2017-01-21
PCT/CN2017/108100 WO2018077246A1 (zh) 2016-10-28 2017-10-27 用作神经营养因子酪氨酸激酶受体抑制剂的氨基吡唑并嘧啶化合物

Publications (2)

Publication Number Publication Date
KR20190067913A KR20190067913A (ko) 2019-06-17
KR102616249B1 true KR102616249B1 (ko) 2023-12-21

Family

ID=62024344

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197015241A Active KR102616249B1 (ko) 2016-10-28 2017-10-27 신경영양성 인자인 티로신 키나제 수용체 억제제로서 사용되는 아미노 피라졸로피리미딘 화합물

Country Status (15)

Country Link
US (1) US10829492B2 (https=)
EP (1) EP3533796B1 (https=)
JP (1) JP7046940B2 (https=)
KR (1) KR102616249B1 (https=)
CN (1) CN109890820B (https=)
AU (1) AU2017348826B2 (https=)
CA (1) CA3041942C (https=)
DK (1) DK3533796T3 (https=)
ES (1) ES2896943T3 (https=)
HU (1) HUE057733T2 (https=)
MX (1) MX380283B (https=)
PL (1) PL3533796T3 (https=)
PT (1) PT3533796T (https=)
RU (1) RU2764523C2 (https=)
WO (1) WO2018077246A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11286264B2 (en) * 2017-07-28 2022-03-29 Turning Point Therapeutics, Inc. Macrocyclic compounds and uses thereof
DK3674307T3 (da) 2017-08-23 2023-09-11 Chia Tai Tianqing Pharmaceutical Group Co Ltd Makrocyklus indeholdende aminopyrazol og pyrimidin og farmaceutisk sammensætning og anvendelse deraf
CN108794370A (zh) * 2018-07-31 2018-11-13 上海弈柯莱生物医药科技有限公司 一种拉罗替尼中间体的制备方法
CA3122136A1 (en) * 2018-12-07 2021-06-11 Betta Pharmaceuticals Co., Ltd Tyrosine kinase inhibitors, compositions and methods there of
JP7209415B2 (ja) 2019-03-19 2023-01-20 セントラル チャイナ ノーマル ユニバーシティ ピラゾロピリミジン化合物、医薬組成物、及びその使用
CN112979654B (zh) * 2019-12-16 2024-03-19 赛诺哈勃药业（成都）有限公司 杂芳基稠环化合物、其制备方法及应用
TW202214635A (zh) * 2020-06-11 2022-04-16 大陸商貝達藥業股份有限公司 酪氨酸激酶抑制劑的鹽型、晶型、藥物組合物及其用途
CN111620881B (zh) * 2020-07-08 2023-03-31 浙江合聚生物医药有限公司 拉罗替尼衍生物及其制备方法和应用
CN113563343B (zh) * 2020-07-27 2022-05-24 杭州邦顺制药有限公司 取代的吡唑并[1,5-a]嘧啶化合物及其用途
CN112010860B (zh) * 2020-08-05 2023-03-10 南京纳丁菲医药科技有限公司 苄氧基吡唑并嘧啶化合物和药物组合物及其应用
CN114437075B (zh) * 2020-11-03 2026-01-30 上海瑶琪生物科技有限公司 用作ntrk激酶抑制剂的化合物及其应用
CN113200963A (zh) * 2021-03-31 2021-08-03 广东石油化工学院 N-(吡咯基)-3-吡唑基胺及其制备方法
JP7840066B2 (ja) * 2021-05-03 2026-04-03 ジェービーケーラボ カンパニー リミテッド ２，６－ジクロロ－４－（４－（４－ヒドロキシシクロヘキシルアミノ）－７ｈ－ピロロ［２，３－ｄ］ピリミジン－５－イル）フェノールを活性成分として含有する、がんを予防、緩和、または処置するための医薬組成物
CN117751121A (zh) * 2021-07-30 2024-03-22 正大天晴药业集团股份有限公司 氨基吡唑并嘧啶化合物的晶体
WO2023011616A1 (zh) * 2021-08-06 2023-02-09 正大天晴药业集团股份有限公司 氨基吡唑并嘧啶化合物在治疗trk激酶介导的肿瘤中的用途
CN117088800B (zh) * 2023-08-18 2024-05-28 龙曦宁（上海）医药科技有限公司 一种5-甲基吡咯烷-3-醇盐酸盐的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
WO2016097869A1 (en) * 2014-12-15 2016-06-23 Cmg Pharmaceutical Co., Ltd. Fused ring heteroaryl compounds and their use as trk inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10356579A1 (de) 2003-12-04 2005-07-07 Merck Patent Gmbh Aminderivate
WO2009140128A2 (en) 2008-05-13 2009-11-19 Irm Llc Compounds and compositions as kinase inhibitors
RU2509078C2 (ru) 2008-07-01 2014-03-10 Дженентек, Инк. Бициклические гетероциклы в качестве ингибиторов киназы мек
PT2350075E (pt) 2008-09-22 2014-06-09 Array Biopharma Inc Compostos imidazo[1,2b]piridazina substituídos como inibidores da trk cinase
AR074052A1 (es) * 2008-10-22 2010-12-22 Array Biopharma Inc Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
WO2012116217A1 (en) 2011-02-25 2012-08-30 Irm Llc Compounds and compositions as trk inhibitors
WO2013028263A1 (en) 2011-08-24 2013-02-28 Glaxosmithkline Llc Pyrazolopyrimidine derivatives as pi3 kinase inhibitors
KR20140105508A (ko) * 2011-12-12 2014-09-01 닥터 레디스 레보러터리즈 리미티드 트로포미오신 수용체 키나제(Trk) 억제제인 치환된 피라졸로[1,5-a]피리딘
MX362181B (es) 2013-02-19 2019-01-08 Ono Pharmaceutical Co Compuesto inhibidor de cinasa del receptor de tropomiosina (trk).
WO2014143242A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CN104650092B (zh) * 2013-11-16 2017-11-10 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
DK3077397T3 (da) * 2013-12-06 2019-12-16 Vertex Pharma 2-amino-6-fluor-n-[5-fluor-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamidforbindelse anvendelig som atr-kinase-inhibitor, dens fremstilling, forskellige faste former og radiomarkerede derivater deraf

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
WO2016097869A1 (en) * 2014-12-15 2016-06-23 Cmg Pharmaceutical Co., Ltd. Fused ring heteroaryl compounds and their use as trk inhibitors

Also Published As

Publication number Publication date
PL3533796T3 (pl) 2022-01-17
CN109890820B (zh) 2020-11-03
US10829492B2 (en) 2020-11-10
MX380283B (es) 2025-03-12
EP3533796B1 (en) 2021-09-29
RU2019114600A3 (https=) 2021-02-20
US20190352306A1 (en) 2019-11-21
CA3041942C (en) 2023-03-14
MX2019004847A (es) 2019-08-29
KR20190067913A (ko) 2019-06-17
BR112019008656A8 (pt) 2022-06-07
ES2896943T3 (es) 2022-02-28
WO2018077246A1 (zh) 2018-05-03
AU2017348826B2 (en) 2021-12-02
DK3533796T3 (da) 2021-11-08
EP3533796A4 (en) 2020-06-03
BR112019008656A2 (pt) 2019-07-09
PT3533796T (pt) 2021-11-18
EP3533796A1 (en) 2019-09-04
RU2019114600A (ru) 2020-11-30
JP7046940B2 (ja) 2022-04-04
JP2019537588A (ja) 2019-12-26
CA3041942A1 (en) 2018-05-03
CN109890820A (zh) 2019-06-14
AU2017348826A1 (en) 2019-05-23
HUE057733T2 (hu) 2022-06-28
RU2764523C2 (ru) 2022-01-18

Similar Documents

Publication Publication Date Title
KR102616249B1 (ko) 신경영양성 인자인 티로신 키나제 수용체 억제제로서 사용되는 아미노 피라졸로피리미딘 화합물
JP7644517B2 (ja) Ｋｒａｓ突然変異型タンパク質阻害剤
CN111153901B (zh) 一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途
ES2857251T3 (es) Compuestos polifluorados que actúan como inhibidores de la tirosina cinasa de bruton
KR102619444B1 (ko) 아미노피라졸 및 피리미딘을 함유하는 마크로사이클 및 그의 약학적 조성물 및 용도
WO2012058645A1 (en) Heterocyclic tyrosine kinase inhibitors
EP3546458B1 (en) ((pyridin-2-yl)-amino)pyrido[3,4-d]pyrimidine and ((pyridazin-3-yl)-amino)pyrido[3,4-d]pyrimidine derivatives as cdk4/6 inhibitors for treating e.g. rheumatoid arthritis, arteriosclerosis, pulmonary fibrosis, cerebral infarction or cancer
JP2023515095A (ja) 置換アリール系化合物
ES3036245T3 (en) Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer
CN113045569A (zh) 用作ret激酶抑制剂的化合物及其应用
TW202500564A (zh) 週期素抑制劑
BR112019008656B1 (pt) Composto de aminopirazolopirimidina, composição farmacêutica que compreende o mesmo e uso do dito composto para a profilaxia ou o tratamento de uma doença mediada por receptor de tirosina quinase de fator neurotrófico
RU2779497C2 (ru) Макроцикл, содержащий аминопиразол и пиримидин, и его фармацевтическая композиция и применение
HK40002935A (en) Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor
HK40002935B (en) Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor
HK40019194B (en) Macrocycle containing aminopyrazole and pyrimidine and pharmaceutical composition and use thereof
HK40019194A (en) Macrocycle containing aminopyrazole and pyrimidine and pharmaceutical composition and use thereof
HK40029944B (en) Nitrogen-containing fused heterocyclic shp2 inhibitor compound, preparation method, and use
HK40029944A (en) Nitrogen-containing fused heterocyclic shp2 inhibitor compound, preparation method, and use
HK40050826B (zh) Akt抑制剂

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601